Risk adjusted net present value: What is the current valuation of Eli Lilly and Co’s Imlunestrant tosylate?
Imlunestrant tosylate is a small molecule commercialized by Eli Lilly and Co, with a leading Phase III program in Metastatic Breast Cancer.
Imlunestrant tosylate is a small molecule commercialized by Eli Lilly and Co, with a leading Phase III program in Metastatic Breast Cancer.
What's Your Reaction?
